Axio BioPharma raises $2.4M to connect manufacturing data across biopharma partners

Axio BioPharma closed a $2.4 million pre-seed round to deploy its Axio Lattice platform with pharma and manufacturing partners. The Madison company says the system is built to reduce manual data handoffs across companies without moving data into a central repository.

Why it matters: - Biopharma teams still rely on documents, spreadsheets and manual mapping when a program moves between pharma companies, manufacturing partners and testing labs. - Axio BioPharma is targeting that handoff problem with software that keeps data connected across organizations while each company keeps its own systems and data ownership. - The company says that could shorten tech transfer work, reduce friction in investigations and give AI models a fuller picture of a program.

What happened: - Axio BioPharma closed a $2.4 million pre-seed financing round. - Elmstead Partners, Chisos Capital, the Chemical Angel Network and individual angel investors participated in the round. - The company will use the money for initial Axio Lattice deployments and continued development of Rosetta, Lattice’s ontology mapping layer. - Axio BioPharma is based in Madison, Wisconsin.

The details: - Rosetta maps differences in terminology, structure and context so information stays understandable and comparable across organizations. - Axio Lattice connects manufacturing information across pharma companies and manufacturing partners without requiring a central repository. - The platform is designed to let each company keep its existing systems in place. - Axio Forge, the company’s high-throughput research-grade monoclonal antibody laboratory in Madison, grounds the product development work in real lab workflows. - Axio’s first Lattice node operates at Forward BioLabs, where Forge is based. - Axio says Forge produces purified antibodies in 3 to 5 weeks from sequence. - The company plans to work directly with design partners on tech transfer and investigations, two workflows where cross-company data gaps are especially painful. - The company’s website is more information.

Between the lines: - Axio is building around the reality that modern biomanufacturing is fragmented across separate organizations, each with its own systems and standards. - The approach is less about replacing existing tools and more about making them interoperable. - The new funding also signals investor interest in infrastructure that supports data flow, not just laboratory automation or drug development. - The company’s recent partnerships with Ansa Biotechnologies, The BioForge and Plug and Play Lifetech suggest it is trying to embed itself in the broader biologics development ecosystem. - Elmstead Partners said Axio is addressing an important operational challenge for the biopharmaceutical industry and called it one of Elmstead’s highest-conviction investments.

What's next: - Axio plans to roll out initial Lattice deployments with design partners. - The company will keep expanding Rosetta around the way biomanufacturing teams actually work. - Axio expects Lattice to support more cross-company workflows as it scales beyond the first node at Forward BioLabs. - Further partnership activity could follow as the company builds on its current ties across gene synthesis, development workflows and accelerator programs.

The bottom line: - Axio BioPharma is betting that the next big biomanufacturing efficiency gain comes from connecting data between companies, not just digitizing each company separately.